Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine

The aim of this study was to confirm the predictive/prognostic value of the preadjuvant Glasgow Prognostic Score (GPS) and carbohydrate antigen (CA) 19-9 level in pancreatic cancer patients receiving adjuvant gemcitabine (GEM) after surgery. A total of 67 resected pancreatic cancer patients, treated...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2016-05, Vol.36 (5), p.2467-2474
Main Authors: Numata, Koji, Morinaga, Soichiro, Katayama, Yusuke, Sawazaki, Sho, Numata, Masakatsu, Godai, Teni, Higuchi, Akio, Shiozawa, Manabu, Rino, Yasushi, Masuda, Munetaka, Akaike, Makoto
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - therapeutic use
CA-19-9 Antigen - blood
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Female
Humans
Male
Middle Aged
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - pathology
Pancreatic Neoplasms - surgery
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to confirm the predictive/prognostic value of the preadjuvant Glasgow Prognostic Score (GPS) and carbohydrate antigen (CA) 19-9 level in pancreatic cancer patients receiving adjuvant gemcitabine (GEM) after surgery. A total of 67 resected pancreatic cancer patients, treated with adjuvant GEM, were included. The GPS and CA19-9 level were calculated prior to administration of adjuvant therapy and were found to correlate with the outcomes and rate of early recurrence. An elevated preadjuvant GPS or CA19-9 level was significantly associated with a shorter overall survival (OS) (p=0.003 and p
ISSN:1791-7530